Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results
The research conducted in this preclinical study assesses QazCovid-live, a live attenuated COVID-19 vaccine created in Kazakhstan, by conducting preclinical evaluations of safety, immunogenicity, and allergenicity in various animal models, including mice, rats, hamsters, and guinea pigs. The vaccine...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/12/1401 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846102417017405440 |
|---|---|
| author | Lespek Kutumbetov Balzhan Myrzakhmetova Aiganym Tussipova Gulzhan Zhapparova Talshyngul Tlenchiyeva Karina Bissenbayeva Kuanysh Zhapar Kuandyk Zhugunissov Sergazy Nurabayev Aslan Kerimbayev |
| author_facet | Lespek Kutumbetov Balzhan Myrzakhmetova Aiganym Tussipova Gulzhan Zhapparova Talshyngul Tlenchiyeva Karina Bissenbayeva Kuanysh Zhapar Kuandyk Zhugunissov Sergazy Nurabayev Aslan Kerimbayev |
| author_sort | Lespek Kutumbetov |
| collection | DOAJ |
| description | The research conducted in this preclinical study assesses QazCovid-live, a live attenuated COVID-19 vaccine created in Kazakhstan, by conducting preclinical evaluations of safety, immunogenicity, and allergenicity in various animal models, including mice, rats, hamsters, and guinea pigs. The vaccine, developed by attenuating SARS-CoV-2 via numerous Vero cell passages, had no significant adverse effects in acute and subacute toxicity assessments, even at elevated dosages. Allergenicity testing indicated the absence of both immediate and delayed hypersensitivity reactions. Immunogenicity evaluations revealed strong virus-neutralizing antibody responses, especially following intranasal and intratracheal delivery. Studies on reversibility and transmission further validated the vaccine’s stability and non-pathogenicity. The data indicate that QazCovid-live is safe, immunogenic, and prepared for clinical trials, presenting a potential strategy for COVID-19 prevention. |
| format | Article |
| id | doaj-art-4be9b2f0ea0e4628be51ce27a72cd9a8 |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-4be9b2f0ea0e4628be51ce27a72cd9a82024-12-27T14:58:06ZengMDPI AGVaccines2076-393X2024-12-011212140110.3390/vaccines12121401Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study ResultsLespek Kutumbetov0Balzhan Myrzakhmetova1Aiganym Tussipova2Gulzhan Zhapparova3Talshyngul Tlenchiyeva4Karina Bissenbayeva5Kuanysh Zhapar6Kuandyk Zhugunissov7Sergazy Nurabayev8Aslan Kerimbayev9Research Institute for Biological Safety Problems, Gvardeiskiy 080409, KazakhstanResearch Institute for Biological Safety Problems, Gvardeiskiy 080409, KazakhstanResearch Institute for Biological Safety Problems, Gvardeiskiy 080409, KazakhstanResearch Institute for Biological Safety Problems, Gvardeiskiy 080409, KazakhstanResearch Institute for Biological Safety Problems, Gvardeiskiy 080409, KazakhstanResearch Institute for Biological Safety Problems, Gvardeiskiy 080409, KazakhstanResearch Institute for Biological Safety Problems, Gvardeiskiy 080409, KazakhstanResearch Institute for Biological Safety Problems, Gvardeiskiy 080409, KazakhstanResearch Institute for Biological Safety Problems, Gvardeiskiy 080409, KazakhstanResearch Institute for Biological Safety Problems, Gvardeiskiy 080409, KazakhstanThe research conducted in this preclinical study assesses QazCovid-live, a live attenuated COVID-19 vaccine created in Kazakhstan, by conducting preclinical evaluations of safety, immunogenicity, and allergenicity in various animal models, including mice, rats, hamsters, and guinea pigs. The vaccine, developed by attenuating SARS-CoV-2 via numerous Vero cell passages, had no significant adverse effects in acute and subacute toxicity assessments, even at elevated dosages. Allergenicity testing indicated the absence of both immediate and delayed hypersensitivity reactions. Immunogenicity evaluations revealed strong virus-neutralizing antibody responses, especially following intranasal and intratracheal delivery. Studies on reversibility and transmission further validated the vaccine’s stability and non-pathogenicity. The data indicate that QazCovid-live is safe, immunogenic, and prepared for clinical trials, presenting a potential strategy for COVID-19 prevention.https://www.mdpi.com/2076-393X/12/12/1401QazCOVID-livelive attenuated vaccineSARS-CoV-2COVID-19 preventionpreclinical studyvaccine safety |
| spellingShingle | Lespek Kutumbetov Balzhan Myrzakhmetova Aiganym Tussipova Gulzhan Zhapparova Talshyngul Tlenchiyeva Karina Bissenbayeva Kuanysh Zhapar Kuandyk Zhugunissov Sergazy Nurabayev Aslan Kerimbayev Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results Vaccines QazCOVID-live live attenuated vaccine SARS-CoV-2 COVID-19 prevention preclinical study vaccine safety |
| title | Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results |
| title_full | Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results |
| title_fullStr | Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results |
| title_full_unstemmed | Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results |
| title_short | Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results |
| title_sort | safety and immunogenicity of the live attenuated vaccine qazcovid live against coronavirus infection covid 19 pre clinical study results |
| topic | QazCOVID-live live attenuated vaccine SARS-CoV-2 COVID-19 prevention preclinical study vaccine safety |
| url | https://www.mdpi.com/2076-393X/12/12/1401 |
| work_keys_str_mv | AT lespekkutumbetov safetyandimmunogenicityoftheliveattenuatedvaccineqazcovidliveagainstcoronavirusinfectioncovid19preclinicalstudyresults AT balzhanmyrzakhmetova safetyandimmunogenicityoftheliveattenuatedvaccineqazcovidliveagainstcoronavirusinfectioncovid19preclinicalstudyresults AT aiganymtussipova safetyandimmunogenicityoftheliveattenuatedvaccineqazcovidliveagainstcoronavirusinfectioncovid19preclinicalstudyresults AT gulzhanzhapparova safetyandimmunogenicityoftheliveattenuatedvaccineqazcovidliveagainstcoronavirusinfectioncovid19preclinicalstudyresults AT talshyngultlenchiyeva safetyandimmunogenicityoftheliveattenuatedvaccineqazcovidliveagainstcoronavirusinfectioncovid19preclinicalstudyresults AT karinabissenbayeva safetyandimmunogenicityoftheliveattenuatedvaccineqazcovidliveagainstcoronavirusinfectioncovid19preclinicalstudyresults AT kuanyshzhapar safetyandimmunogenicityoftheliveattenuatedvaccineqazcovidliveagainstcoronavirusinfectioncovid19preclinicalstudyresults AT kuandykzhugunissov safetyandimmunogenicityoftheliveattenuatedvaccineqazcovidliveagainstcoronavirusinfectioncovid19preclinicalstudyresults AT sergazynurabayev safetyandimmunogenicityoftheliveattenuatedvaccineqazcovidliveagainstcoronavirusinfectioncovid19preclinicalstudyresults AT aslankerimbayev safetyandimmunogenicityoftheliveattenuatedvaccineqazcovidliveagainstcoronavirusinfectioncovid19preclinicalstudyresults |